Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy
Identifieur interne : 001565 ( PascalFrancis/Corpus ); précédent : 001564; suivant : 001566Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy
Auteurs : Naomi M. Warren ; Margaret A. Piggott ; Elizabeth Greally ; Michelle Lake ; Andrew J. Lees ; David J. BurnSource :
- Movement disorders [ 0885-3185 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative disorder. In contrast to Parkinson's disease (PD) and dementia with Lewy bodies (DLB), replacement therapy with dopaminergic and cholinergic agents in PSP has been disappointing. The neurochemical basis for this is unclear. Our objective was to measure dopaminergic and cholinergic receptors in the basal ganglia of PSP and control brains. We measured, autoradiographically, dopaminergic (dopamine transporter, 125I PE2I and dopamine D2 receptors, 125I epidepride) and cholinergic (nicotinic α4β2 receptors, 125I 5IA85380 and muscarinic Ml receptors, 3H pirenzepine) parameters in the striatum and pallidum of pathologically confirmed PSP cases (n = 15) and controls (n = 32). In PSP, there was a marked loss of dopamine transporter and nicotinic α4β2 binding in the striatum and pallidum, consistent with loss of nigrostriatal neurones. Striatal D2 receptors were increased in the caudate and muscarinic Ml receptors were unchanged compared with controls. These results do not account for the poor response to dopaminergic and cholinergic replacement therapies in PSP, and suggest relative preservation of postsynaptic striatal projection neurones bearing D2/M1 receptors.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 07-0448795 INIST |
---|---|
ET : | Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy |
AU : | WARREN (Naomi M.); PIGGOTT (Margaret A.); GREALLY (Elizabeth); LAKE (Michelle); LEES (Andrew J.); BURN (David J.) |
AF : | Institute/or Ageing and Heath, University of Newcastle upon Tyne/Newcastle upon Tyne/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Sara Koe PSP Research Centre, Institute of Neurology, University College/London/Royaume-Uni (5 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 11; Pp. 1594-1600; Bibl. 59 ref. |
LA : | Anglais |
EA : | Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative disorder. In contrast to Parkinson's disease (PD) and dementia with Lewy bodies (DLB), replacement therapy with dopaminergic and cholinergic agents in PSP has been disappointing. The neurochemical basis for this is unclear. Our objective was to measure dopaminergic and cholinergic receptors in the basal ganglia of PSP and control brains. We measured, autoradiographically, dopaminergic (dopamine transporter, 125I PE2I and dopamine D2 receptors, 125I epidepride) and cholinergic (nicotinic α4β2 receptors, 125I 5IA85380 and muscarinic Ml receptors, 3H pirenzepine) parameters in the striatum and pallidum of pathologically confirmed PSP cases (n = 15) and controls (n = 32). In PSP, there was a marked loss of dopamine transporter and nicotinic α4β2 binding in the striatum and pallidum, consistent with loss of nigrostriatal neurones. Striatal D2 receptors were increased in the caudate and muscarinic Ml receptors were unchanged compared with controls. These results do not account for the poor response to dopaminergic and cholinergic replacement therapies in PSP, and suggest relative preservation of postsynaptic striatal projection neurones bearing D2/M1 receptors. |
CC : | 002B17; 002B17G; 002B25J01 |
FD : | Système nerveux pathologie; Noyau gris central |
FG : | Encéphale; Système nerveux central |
ED : | Nervous system diseases; Basal ganglion |
EG : | Encephalon; Central nervous system |
SD : | Sistema nervioso patología; Núcleo basal |
LO : | INIST-20953.354000149744800120 |
ID : | 07-0448795 |
Links to Exploration step
Pascal:07-0448795Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy</title>
<author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Piggott, Margaret A" sort="Piggott, Margaret A" uniqKey="Piggott M" first="Margaret A." last="Piggott">Margaret A. Piggott</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Greally, Elizabeth" sort="Greally, Elizabeth" uniqKey="Greally E" first="Elizabeth" last="Greally">Elizabeth Greally</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lake, Michelle" sort="Lake, Michelle" uniqKey="Lake M" first="Michelle" last="Lake">Michelle Lake</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Sara Koe PSP Research Centre, Institute of Neurology, University College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0448795</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0448795 INIST</idno>
<idno type="RBID">Pascal:07-0448795</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001565</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy</title>
<author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M." last="Warren">Naomi M. Warren</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Piggott, Margaret A" sort="Piggott, Margaret A" uniqKey="Piggott M" first="Margaret A." last="Piggott">Margaret A. Piggott</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Greally, Elizabeth" sort="Greally, Elizabeth" uniqKey="Greally E" first="Elizabeth" last="Greally">Elizabeth Greally</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lake, Michelle" sort="Lake, Michelle" uniqKey="Lake M" first="Michelle" last="Lake">Michelle Lake</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Sara Koe PSP Research Centre, Institute of Neurology, University College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation><inist:fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Basal ganglion</term>
<term>Nervous system diseases</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Noyau gris central</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative disorder. In contrast to Parkinson's disease (PD) and dementia with Lewy bodies (DLB), replacement therapy with dopaminergic and cholinergic agents in PSP has been disappointing. The neurochemical basis for this is unclear. Our objective was to measure dopaminergic and cholinergic receptors in the basal ganglia of PSP and control brains. We measured, autoradiographically, dopaminergic (dopamine transporter, <sup>125</sup>
I PE2I and dopamine D2 receptors, <sup>125</sup>
I epidepride) and cholinergic (nicotinic α4β2 receptors, <sup>125</sup>
I 5IA85380 and muscarinic Ml receptors, <sup>3</sup>
H pirenzepine) parameters in the striatum and pallidum of pathologically confirmed PSP cases (n = 15) and controls (n = 32). In PSP, there was a marked loss of dopamine transporter and nicotinic α4β2 binding in the striatum and pallidum, consistent with loss of nigrostriatal neurones. Striatal D2 receptors were increased in the caudate and muscarinic Ml receptors were unchanged compared with controls. These results do not account for the poor response to dopaminergic and cholinergic replacement therapies in PSP, and suggest relative preservation of postsynaptic striatal projection neurones bearing D2/M1 receptors.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WARREN (Naomi M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PIGGOTT (Margaret A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GREALLY (Elizabeth)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LAKE (Michelle)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LEES (Andrew J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BURN (David J.)</s1>
</fA11>
<fA14 i1="01"><s1>Institute/or Ageing and Heath, University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Sara Koe PSP Research Centre, Institute of Neurology, University College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>1594-1600</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000149744800120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>59 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0448795</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative disorder. In contrast to Parkinson's disease (PD) and dementia with Lewy bodies (DLB), replacement therapy with dopaminergic and cholinergic agents in PSP has been disappointing. The neurochemical basis for this is unclear. Our objective was to measure dopaminergic and cholinergic receptors in the basal ganglia of PSP and control brains. We measured, autoradiographically, dopaminergic (dopamine transporter, <sup>125</sup>
I PE2I and dopamine D2 receptors, <sup>125</sup>
I epidepride) and cholinergic (nicotinic α4β2 receptors, <sup>125</sup>
I 5IA85380 and muscarinic Ml receptors, <sup>3</sup>
H pirenzepine) parameters in the striatum and pallidum of pathologically confirmed PSP cases (n = 15) and controls (n = 32). In PSP, there was a marked loss of dopamine transporter and nicotinic α4β2 binding in the striatum and pallidum, consistent with loss of nigrostriatal neurones. Striatal D2 receptors were increased in the caudate and muscarinic Ml receptors were unchanged compared with controls. These results do not account for the poor response to dopaminergic and cholinergic replacement therapies in PSP, and suggest relative preservation of postsynaptic striatal projection neurones bearing D2/M1 receptors.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B25J01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Encephalon</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>38</s5>
</fC07>
<fN21><s1>295</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0448795 INIST</NO>
<ET>Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy</ET>
<AU>WARREN (Naomi M.); PIGGOTT (Margaret A.); GREALLY (Elizabeth); LAKE (Michelle); LEES (Andrew J.); BURN (David J.)</AU>
<AF>Institute/or Ageing and Heath, University of Newcastle upon Tyne/Newcastle upon Tyne/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Sara Koe PSP Research Centre, Institute of Neurology, University College/London/Royaume-Uni (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 11; Pp. 1594-1600; Bibl. 59 ref.</SO>
<LA>Anglais</LA>
<EA>Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative disorder. In contrast to Parkinson's disease (PD) and dementia with Lewy bodies (DLB), replacement therapy with dopaminergic and cholinergic agents in PSP has been disappointing. The neurochemical basis for this is unclear. Our objective was to measure dopaminergic and cholinergic receptors in the basal ganglia of PSP and control brains. We measured, autoradiographically, dopaminergic (dopamine transporter, <sup>125</sup>
I PE2I and dopamine D2 receptors, <sup>125</sup>
I epidepride) and cholinergic (nicotinic α4β2 receptors, <sup>125</sup>
I 5IA85380 and muscarinic Ml receptors, <sup>3</sup>
H pirenzepine) parameters in the striatum and pallidum of pathologically confirmed PSP cases (n = 15) and controls (n = 32). In PSP, there was a marked loss of dopamine transporter and nicotinic α4β2 binding in the striatum and pallidum, consistent with loss of nigrostriatal neurones. Striatal D2 receptors were increased in the caudate and muscarinic Ml receptors were unchanged compared with controls. These results do not account for the poor response to dopaminergic and cholinergic replacement therapies in PSP, and suggest relative preservation of postsynaptic striatal projection neurones bearing D2/M1 receptors.</EA>
<CC>002B17; 002B17G; 002B25J01</CC>
<FD>Système nerveux pathologie; Noyau gris central</FD>
<FG>Encéphale; Système nerveux central</FG>
<ED>Nervous system diseases; Basal ganglion</ED>
<EG>Encephalon; Central nervous system</EG>
<SD>Sistema nervioso patología; Núcleo basal</SD>
<LO>INIST-20953.354000149744800120</LO>
<ID>07-0448795</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001565 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001565 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:07-0448795 |texte= Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy }}
This area was generated with Dilib version V0.6.23. |